Description
|
Catalog #
|
CAS#
|
Target
|
Size
|
Price ( $)
|
Ro-31-8425,
2-[8-(Aminomethyl)-6,7,8,9-tet
rahydropyrido[1,2-a]indol-3-yl]-
3-(1-methyl-1H-indol-3-yl)mal
eimide, HCl,
Bisindolylmaleimide X, HCl
|
SMBC1001
|
131848-97-0
|
Protein kinase C inhibitor.
A potent, cell-permeable,
reversible, ATP-competitive, and
selective protein kinase C inhibitor
(IC50 = 15 nM for rat brain PKC).
|
1mg
|
90
|
Ro-32-0432,
2-{8-[(Dimethylamino)methyl]-
6,7,8,9-tetrahydropyrido[1,2-a]i
ndol-3-yl}-3-(1-methyl-1H-indo
l-3-yl)maleimide, HCl,
Bisindolylmaleimide XI, HCl,
3-(8-((dimethylamino)methyl)-
6,7,8,9-tetrahydropyrido[1,2-a]i
ndol-10-y1)-4-(1-methyl-1H-in
dol-3-y1)-1H-pyrrole-2,5-dione
hydrochloride
|
SMBC1002
|
145333-02-4
|
PKCα
A selective cell-permeable protein
kinase C inhibitor. Displays about
10-fold greater selectivity for PKCα
(IC50 = 9 nM) and 4-fold greater
selectivity for PKCβI (IC50 = 28 nM)
over PKCε (IC50 = 108 nM).
|
1mg
|
115
|
MNK1 Inhibitor,
CGP 57380
4-Amino-5-(4-fluoroanilino)-py
razolo[3,4-d]pyrimidine
|
SMBC1003
|
522629-08-9
|
A cell-permeable, reversible, and
ATP-competitive
pyrazolo-pyrimidine compound that
acts as a selective inhibitor of
mitogen-activated protein
kinase-interacting kinase 1 (MNK1;
IC50 = 2.2 µM) with no inhibitory
activity against p38, JNK1, ERK1/2,
PKC, or Src-like kinases. Effectively
inhibits eIF4E phosphorylation
(IC50 = 3 µM) by MNK1 in 293
human embryonic kidney cells and
serves as a useful tool in studying
MNK1-mediated cellular signaling.
|
5mg
|
150
|
Gö 7874, Hydrochloride
|
SMBC1005
|
287935-76-6
|
A cell-permeable, potent,
reversible, ATP-competitive, and
selective inhibitor of protein kinase
C (IC50 = 4 nM for rat brain PKC).
Inhibits protein kinase A (IC50 =
510 nM), protein kinase G (IC50 =
4.8 µM), and myosin light chain
kinase (IC50 = 120 nM) at much
higher concentrations.
|
500
μg
|
105
|
Merbarone
5-(N-Phenylcarboxamido)-2-th
iobarbituric Acid, NSC-336628
|
SMBC1006
|
97534-21-9
|
catalytic activity of topoisomerase II.
A cell-permeable anticancer drug
that inhibits the catalytic activity of
topoisomerase II (topo II) without
damaging DNA or stabilizing
DNA-topo II cleavable complexes
(IC50 = 20 µM for purified
mammalian topo II versus IC50 = ~
200 µM for topo I). Also induces
apoptosis in human leukemic CEM
cells through a caspase-3-like
protease-dependent mechanism.
|
25 mg
|
75
|
Casein Kinase I Inhibitor,
D4476
CK1 Inhibitor,
4-(4-(2,3-Dihydrobenzo[1,4]di
o
xin-6-yl)-5-pyridin-2-yl-1H-imid
azol-2-yl)benzamide
|
SMBC1007
|
301836-43-1
|
CK1, CK1d
A cell-permeable triaryl substituted
imidazolo compound that acts as a
potent, reversible and relatively
specific ATP-competitive inhibitor of
CK1 (IC50 = 0.2 µM from S. pombe;
0.3 µM for CK1δ) and ALK5 (IC50 =
0.5 µM). A weak inhibitor of p38α
MAP kinase (IC50 = 12 µM) and
only weakly affects the activities of a
panel of kinases tested, including
PKB, SGK and GSK-3β.
Suppresses the site-specific
phosphorylation (Ser322 and
Ser325) and nuclear exclusion of
FOXO1a in H4IIE hepatoma cells.
Shown to be ~10-fold more potent
than IC261 (Cat. No. 400090; IC50
= 2.5 µM for CK1).
|
1mg
|
120
|
SU1498
(E)-3-(3,5-Diisopropyl-4-hydro
xyphenyl)-2-[(3-phenyl-n-propy
l)amino-carbonyl]acrylonitrile
|
SMBC1008
|
|
Flk-1 kinase
A potent, reversible,
ATP-competitive and selective
inhibitor of Flk-1 kinase (IC50 = 700
nM), a vascular endothelial growth
factor (VEGF) receptor kinase. Also
reduces the expression of ets-1, a
transcription factor stimulated by
VEGF.
|
5mg
|
130
|
PD 153035
AG 1517,
4-[(3-Bromophenyl)amino]-6,7
-dimethoxyquinazoline, SU
5271, Compound 32
|
SMBC1009
|
153436-54-5
|
EGFR
An extremely potent,
cell-permeamble, reversible,
ATP-competitive and specific
inhibitor of the tyrosine kinase
activity of the epidermal growth
factor receptor (EGFR; IC50 = 25
pM; Ki = 6 pM). Rapidly suppresses
autophosphorylation of EGFR at
low nanomolar concentrations in
fibroblasts or in human epidermoid
carcinoma cells
|
5mg
|
80
|
LY 231617
2,6-bis(1,1-Dimethylethyl)-4-[[(
1-ethyl)amino]methyl]phenol,
HCl
|
SMBC1012
|
141545-89-3
|
A potent antioxidant that readily
crosses the blood-brain barrier.
Significantly reduces ischemia-
induced or hydrogen peroxide-
induced neuronal damage and
inhibits lipid peroxidation (IC50 =
22 µM). Prevents nuclear
translocation of activated NF-κB in
hippocampal neurons.
|
5mg
|
148
|
SC-68376
2-Methyl-4-phenyl-5-(4-pyridyl)
oxazole
|
SMBC1013
|
318480-82-9
|
A potent, reversible,
cell-permeable, ATP-competitive,
and selective inhibitor of p38 MAP
kinase activity in a dose-dependent
manner (IC50 = 2-5 µM). Does not
inhibit basal ERK or IL-1-induced
JNK activity
|
1mg
|
Discontinued
|
Src Kinase Inhibitor I
4-(4′-Phenoxyanilino)-6,7-
dimethoxyquinazoline
|
SMBC1014
|
179248-59-0
|
Src
A 4′-phenoxy substituted 4-
anilinoquinazoline compound that
acts as a potent, selective, dual
site, cell-permeable, reversible and
ATP-competitive inhibitor of Src
family tyrosine kinases (IC50 = 44
nM and 88 nM for Src and Lck,
respectively).
|
1mg
|
100
|
VEGFR Tyrosine Kinase
Inhibitor III, KRN633
N-(2-Chloro-4-((6,7-
dimethoxy-4-quinazolinyl)oxy)
phenyl)-N′-propylurea, VEGF
Receptor Tyrosine Kinase
Inhibitor III
|
SMBC1015
|
286370-15-8
|
A cell-permeable, reversible, ATP-
competitive inhibitor of VEGFR
kinase activity (IC50 = 170 nM, 160
nM, and 125 nM for VEGFR-1,
VEGFR-2, VEGFR-3, respectively).
Inhibits PDGFR-α and c-Kit only at
higher concentrations (IC50 = 0.97
µM and 4.33 µM, respectively) and
is inactive towards a panel of 17
other kinases (IC50 ≥ 10 µM).
|
1mg
|
150
|
VEGFR Tyrosine Kinase
Inhibitor III, KRN633
N-(2-Chloro-4-((6,7-
dimethoxy-4-quinazolinyl)oxy)
phenyl)-N′-propylurea, VEGF
Receptor Tyrosine Kinase
Inhibitor III
|
SMBC1015
|
286370-15-8
|
A cell-permeable, reversible, ATP-
competitive inhibitor of VEGFR
kinase activity (IC50 = 170 nM, 160
nM, and 125 nM for VEGFR-1,
VEGFR-2, VEGFR-3, respectively).
Inhibits PDGFR-α and c-Kit only at
higher concentrations (IC50 = 0.97
µM and 4.33 µM, respectively) and
is inactive towards a panel of 17
other kinases (IC50 ≥ 10 µM).
|
10 mg
|
360
|
3,4-dichloro-N-(naphthalen-2-yl)benzamide (NSC 158959)
|
SMBC10613
|
199726-92-6
|
MicroRNA miR-122 Inhibitor.
MicroRNA miR-122 is a liver
specific miRNA and the most
abundant miRNA in the liver which
is involved in hepatocellular
carcinoma development and
hepatitis C virus (HCV) infection.
Small molecule inhibitors reduce
viral replication in liver cells and
represent a new approach to the
treatment of HCV infections. NSC
158959 induce a 773 +/- 38%
increase in the relative luciferase
signal.
|
5mg
|
350
|
6-(Octahydroquinolin-1(2H)-ylsulfonyl)-1,2,3,4-tetrahydroquinoline (NSC 5476)
|
SMBC10614
|
902263-48-3
|
MicroRNA miR-122 Inhibitor.
MicroRNA miR-122 is a liver
specific miRNA and the most
abundant miRNA in the liver which
is involved in hepatocellular
carcinoma development and
hepatitis C virus (HCV) infection.
Small molecule inhibitors reduce
viral replication in liver cells and
represent a new approach to the
treatment of HCV infections. The
compound NSC 308847 induce a
1251 +/- 125% increase in the
relative luciferase signal.
|
5mg
|
390
|
5-Amino-2-(2-(dimethylamino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione
(NSC 308847)
|
SMBC10615
|
69408-81-7
|
miR-122 activator.
MicroRNA miR-122 is a liver
specific miRNA and the most
abundant miRNA in the liver which
is involved in hepatocellular
carcinoma development and
hepatitis C virus (HCV) infection.
Small molecule inhibitors reduce
viral replication in liver cells and
represent a new approach to the
treatment of HCV infections. The
compound NSC 308847 induce a
1251 +/- 125% increase in the
relative luciferase signal.
|
5mg
|
175
|
E-64d, Loxistatin
|
SMCUS345
|
|
Calpain/
CathepsinF,K,B,H,L
|
1 mg
|
75
|
E-64d, Loxistatin
|
SMCUS345
|
|
Calpain/
CathepsinF,K,B,H,L
|
5 MG
|
195
|
